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I ntegrated positron emission tomography/com-puted tomography (PET/CT) with 2-[18F]fluo-
ro-2-deoxy D-glucose (FDG) has been shown to be a 
useful tool for combined metabolic and anatomic eval-
uations of cancers.  Although FDG,  an analog of glu-
cose that can visualize metabolic activity,  is the most 
widely used radiotracer for the imaging of various 
malignancies,  its application in cases of prostate cancer 
is limited because of its low sensitivity and speciﬁcity 
[1 , 2].  Moreover,  a urinary excretion of FDG in the 
urinary bladder may interfere with evaluation of pros-
tate lesions.  Many new tracers have been introduced to 
overcome these limitations,  including 18F- or 
11C-choline,  18F- or 11C-acetate,  16β-18F-fluoro-5α-di-
hydrotestosterone (18F-FDHT),  anti-3-18F-fluorocy-
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We compared 11C-choline and FDG PET/CT scan findings for the staging and restaging of prostate cancer.  
Twenty Japanese prostate cancer patients underwent 11C-choline and FDG PET/CT before (n = 5) or after 
(n = 15) treatment.  Using a five-point scale,  we compared these scanning modalities regarding patient- and 
lesion-based diagnostic performance for local recurrence,  untreated primary tumor,  and lymph node and bony 
metastases.  Of the 20 patients,  documented local lesions,  and node and bony metastases were present in 11 
(55.0%),  9 (45.0%),  and 13 (65.0%),  respectively.  The patient-based sensitivity/specificity/accuracy/area under 
the receiver-operating-characteristic curve (AUC) values for 11C-choline-PET/CT for diagnosing local lesions 
were 90.9% / 100% / 95.0% / 1.0,  whereas those for FDG-PET/CT were 45.5% / 100% / 75.0% / 0.773.  Those for 
11C-choline-PET/CT for node metastasis were 88.9% / 100% / 95.0% / 0.944,  and those for FDG-PET/CT were 
44.4% / 100% / 75.0% / 0.722.  Those for 11C-choline-PET/CT for bone metastasis were 84.6% / 100% / 90.0% / 0.951,  
and those for FDG-PET/CT were 76.9% / 100% / 85.0% / 0.962.  The AUCs for local lesion and node metastasis 
differed significantly (p= 0.0039,  p= 0.011,  respectively).  The lesion-based detection rates of 11C-choline com-
pared to FDG PET/CT for local lesion,  and node and bone metastases were 91.7% vs.  41.7%,  92.0% vs.  32.0%,  
and 94.8% vs. 83.0% (p= 0.041,  p= 0.0030,  p< 0.0001),  respectively.  11C-choline-PET/CT is more useful for the 
staging and restaging of prostate cancer than FDG-PET/CT in Japanese men.
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clobutane-1-carboxylic acid (18F-FACBC),  and pros-
tate-speciﬁc membrane antigen (68Ga-PSMA),  which 
are currently under investigation [2].
In Western countries,  11C- and 18F-choline PET/CT 
examinations have been successfully used for the 
restaging of prostate cancer in patients who exhibit bio-
chemical disease recurrence after they underwent 
deﬁnitive therapy [3 , 4].  However,  11C-choline uptake 
may occur via a choline-speciﬁc transporter protein that 
is overexpressed in the membrane of prostate cancer 
cells [5].  11C-choline is phosphorylated by choline 
kinase,  which is upregulated and retained within tumor 
cells for the synthesis of phosphatidylcholine [5],  an 
essential component of cell membranes involved in the 
modulation of transmembrane signaling during car-
cinogenesis.
Four research groups have directly compared the 
diagnostic performance of choline-PET/CT with that of 
FDG-PET/CT for the staging and restaging prostate 
cancer in non-Japanese men [6-9],  of which three 
reported the superiority of choline PET/CT [6-8] and 
the fourth reported that the diagnostic performance of 
each was the same [9].  Thus,  the true superiority of 
choline PET/CT has yet to be conﬁrmed in Japanese 
men.  We conducted the present study to compare the 
ﬁndings obtained with 11C-choline PET/CT with those 
obtained with FDG-PET/CT for the staging and restag-
ing of prostate cancer in Japanese men.
Patients and Methods
Patients. This retrospective study was approved 
by the ethics committee at our institution (no. 2213).  
Informed consent was obtained from each patient after 
the procedure details were fully explained.  A total of 20 
patients (age range 50-90 years,  mean 70.8 years) with 
histopathologically proven prostate cancer underwent 
11C-choline PET/CT and FDG-PET/CT examinations at 
a maximum interval of 2 weeks for the staging (n = 5) 
and restaging (n = 15) of prostate cancer at our institu-
tion between October 2015 and June 2017,  and all were 
included in this study.  The median free serum prostate 
speciﬁc antigen (PSA) level in the ﬁve patients who 
underwent both examinations before treatment was 
104 ng/mL (range 3.0-5,916.6 ng/mL),  and that in the 
15 who underwent both examinations during or after 
treatment was 10.1 (range 2.1-1,274.4 ng/mL).  At the 
time of the examinations,  14 of the 20 patients (70.0%) 
had received androgen-deprivation therapy.  Additional 
patient details and demographic data are shown in 
Table 1.
11C-choline PET/CT. 11C-choline was synthesized 
using a commercial module as described by Hara [10] 
and an CYPRIS-325R cyclotron (Sumitomo Heavy 
Industries [SHI],  Tokyo,  Japan).  The acquisition of 
emission scans from the mid-thigh to the head was 
started 6 min after an intravenous injection of 
3.0 MBq/kg body weight of 11C-choline.  All PET/CT 
examinations were performed using a PET/CT scanner 
equipped with a 64-multi-detector computed tomogra-
phy device (Gemini TF64; Philips Medical Systems,  
Eindhoven,  The Netherlands).  Whole-body PET 
acquisition in 3D mode was performed from the mid-
thigh to the top of the head (1.5 min per bed posi-
tion; 6-8 bed positions) and reconstructed using the 
ordered subsets expectation maximization (OSEM) 
reconstruction algorithm (33 subsets,  three iterations,  
4 mm per slice) with attenuation correction based on 
low-dose CT (120 kVp,  100 mA,  slice thickness 2 mm,  
transverse ﬁeld of view 600 mm),  which was also used 
for anatomical correlation.
FDG PET/CT. FDG was synthesized suing the 
nucleophilic substitution method with an FDG-
synthesizing instrument F-200 (SHI) and CYPRIS-325R 
cyclotron (SHI).  Patients were instructed to fast for 5 h 
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Table 1　 Patient characteristics
Characteristics value
Age (years)
Mean 70.8±9.4
Range 50～90
PSA (ng/mL)
Patients without any previous treatments (n=5)
Mean 1,249.8±2,609.8
Range 3.0～5,916.6
Median 104
Patients with previous treatments (n=15)
Mean 101.3±324.9
Range 2.1～1,274.4
Median 10.1
Previous treatment
None 5
Radiotherapy 1
Radiotherapy＋Hormonal therapy 6
Hormonal therapy 7
Hormonal therapy＋Chemotherapy 1
PSA: prostate speciﬁc antigen
prior to scanning,  and blood glucose was measured 
immediately before an injection of 3.0 MBq/kg body 
weight of FDG.  None of the patients had a blood glu-
cose level > 160 mg/dL.  Whole-body FDG-PET/CT was 
performed 60 min after the injection of FDG from the 
top of the head to the mid-thigh,  with the same acqui-
sition and reconstruction parameters noted above for 
11C-choline PET/CT.  No indwelling catheter or diuretic 
was used.  The median time between the 11C-choline 
and FDG PET/CT scanning procedures was 9 days.
Imaging analysis. Two experienced nuclear 
medicine experts (both with at least 9 years of experi-
ence with PET/CT) who had no knowledge of the other 
imaging results or clinical data prospectively inter-
preted the 11C-choline and FDG PET/CT images.  They 
then used a ﬁve-point scale (1: deﬁnitely absent,  
2: probably absent,  3: indeterminate,  4: probably 
present,  5: deﬁnitely present) to grade the lesions in 
each patient based on consensus.  Discordant readings 
by the two observers for each modality were resolved in 
a subsequent consensus review.  To calculate the sensi-
tivity and speciﬁcity of each modality,  scores of 3,  4 
and 5 were considered positive.
A semiquantitative analysis of abnormal radiotracer 
uptake for each lesion was also retrospectively per-
formed using the maximum standardized uptake value 
(SUVmax),  calculated as follows: SUV = volume of 
interest (VOI) radioactivity concentration (Bq/mL)/
[injected dose (Bq)/patient weight (g)].  The SUVmax,  
deﬁned as the highest SUV value for the pixels with the 
highest count within the VOI,  was measured and 
recorded for the focal areas of uptake.
Gold standard. The ﬁnal diagnosis was obtained 
based on histological conﬁrmation,  radiological imag-
ing ﬁndings obtained in subsequent magnetic resonance 
imaging (MRI),  computed tomography (CT),  and bone 
scintigraphy examinations,  or at clinical follow-up 
including the PSA level,  MRI,  CT,  bone scintigraphy,  
and FDG-PET/CT or 11C-choline PET/CT results.
Statistical analysis. We conducted a receiver-op-
erating-characteristic (ROC) analysis to evaluate the 
diagnostic performance of each imaging modality.  We 
also used an ROC contrast estimation to compare the 
diagnostic capability of the 2 modalities on a per-pa-
tient basis.  In the determination of whether the area 
under the ROC curve (AUC) values were different,  the 
correlation of the testing methods was accounted for in 
the analysis.  Tests for differences in sensitivity,  speci-
ﬁcity,  and accuracy between the imaging modalities 
were conducted with the McNemar test.  We also exam-
ined whether there was a signiﬁcant difference in the 
mean SUVmax for local lesions,  lymph node metasta-
sis,  bone metastasis,  and all lesions between 
11C-choline and FDG PET/CT by using a paired t-test.  
P-values < 0.05 were considered signiﬁcant.  All statisti-
cal analyses were performed using SAS software (ver.  
9.3; SAS Institute,  Cary,  NC,  USA).
Results
Local recurrence or primary prostate tumor.
Eleven (55%) of the 20 patients were shown to have 12 
local recurrent or primary lesions (7 local recurrent 
lesions,  5cases of untreated primary prostate cancer).  
The 7 local recurrent lesions consisted of 5 in the pros-
tate gland and 2 in the seminal vesicles.  In the 5 pre-
treatment patients,  11C-choline PET/CT was able to 
detect all 5 cases of prostate cancer,  whereas FDG-
PET/CT detected only 3.  In the 15 posttreatment 
patients,  11C-choline PET/CT was able to detect four of 
5 intra-prostate recurrent lesions and both of the 2 sem-
inal vesicle lesions,  whereas FDG-PET/CT detected 
only 2 of the 4 intra-prostate recurrent lesions.
The patient-based and lesion-based sensitivities of 
11C-choline PET/CT compared to FDG-PET/CT were 
90.9% (10/11) versus 45.5% (5/11) and 91.7% (11/12) 
versus 41.7% (5/12) (p = 0.074 and p = 0.041),  respec-
tively (Tables 2 , 3).  The SUVmax values for the 12 
locally recurrent lesions shown by both 11C-choline 
PET/CT and FDG-PET/CT were 6.18 ± 2.57 and 
3.71 ± 5.06,  respectively (p = 0.044) (Table 3).  A repre-
sentative case is shown in Fig. 1.
Lymph node metastasis. Nine (45%) of the 
20 patients were shown to have 25 metastatic lymph 
nodes (6 outer inguinal,  5 inter-inguinal,  2 obturator,  
2 common inguinal,  5 para-aortic,  2 mediastinal,  2 
supraclavicular,  1 inguinal).  The patient- and lesion-
based sensitivity of 11C-choline PET/CT compared to 
FDG-PET/CT was 88.9% (8/9) versus 44.4% (4/9) and 
92.0% (23/25) versus 32.0% (8/25) (p = 0.13 and 
p = 0.0030),  respectively (Tables 2 , 3).  Two false-nega-
tive cases determined by 11C-choline PET/CT were tiny 
para-aortic metastatic nodes measuring 4 and 5 mm.  
The SUVmax values of the 25 metastatic nodes shown 
by both 11C-choline PET/CT and FDG-PET/CT were 
6.88 ± 3.69 and 1.54 ± 2.06,  respectively (p < 0.00001) 
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Table 2　 Patient-based diagnostic result of 11C-choline PET/CT and FDG-PET/CT
Senstivity 
95%CI
Speciﬁcity 
95%CI
Accuracy 
95%CI
AUC 
95%CI
Local Recurrence or untreated primary tumor
11C-Choline PET/CT 90.9% (10/11) 100% (9/9) 95.0% (19/20) 1.0
73.9～100% 100% 85.4～100%
FDG-PET/CT 45.5% (5/11) 100% (9/9) 70.0% (14/20) 0.773
16.0～74.9% 100% 49.9～90.1% 0.585-0.891
p value 0.074 1.0 0.074 0.0039
Lymph node metastasis
11C-Choline PET/CT 88.9% (8/9) 100% (11/11) 95.0% (19/20) 0.944
68.3～100 % 85.4～100% 0.681-0.993
FDG-PET/CT 44.4% (4/9) 100% (11/11) 75.0% (15/20) 0.722
12.0～76.9% 56.0～94.0% 0.524-0.860
p value 0.13 1.0 0.13 0.011
Bone metastasis
11C-Choline PET/CT 84.6% (11/13) 100% (7/7) 90.0% (18/20) 0.951
65.0～100% 76.9～100% 0.745-0.992
FDG-PET/CT 76.9% (10/13) 100% (7/7) 85.0% (17/20) 0.962
54.0～99.8% 69.4～100% 0.765-0.995
p value 1.0 1.0 1.0 0.851
All lesions
11C-Choline PET/CT 94.4% (17/18) 100% (2/2) 95.0% (19/20) 1.0
83.9～100% 85.4～100%
FDG-PET/CT 66.7% (12/18) 100% (2/2) 70.0% (14/20) 0.889
44.9～88.4% 44.9～90.1% 0.746-0.956
p value 0.074 1.0 0.074 0.028
AUC,  area under the receiver-operating-characteristic curves; CI,  conﬁdence interval; PET/CT,  positron emission tomography/computed 
tomography.
Table 3　 Lesion-based diagnostic sensitivity of 11C-choline PET/CT and FDG PET/CT
11C-choline PET/CT FDG PET/CT p value
Local Recurrence or primary tumor
Sensitivity 91.7% (11/12) 41.7% (5/12) 0.041
95% CI 76.0～100% 13.8～69.6%
SUVmax 6.18±2.57 3.71±5.06 0.044
Lymph node metastasis
Sensitivity 92.0% (23/25) 32.0% (8/25) 0.00030
95% CI 81.4～100% 13.7～50.3%
SUVmax 6.88±3.69 1.54±2.06 <0.0001
Bone metastasis
Sensitivity 94.8% (145/153) 83.0% (127/153) <0.0001
95% CI 91.2～98.3% 77.1～89.0%
SUVmax 5.59±2.60 4.43±2.96 <0.0001
All lesions
Sensitivity 94.2% (179/190) 73.7% (140/190) <0.0001
95% CI 90.9～97.5% 67.4～79.9%
SUVmax 5.79±2.79 4.00±3.16 <0.0001
PET/CT,  positron emission tomography/computed tomography; CI,  conﬁdence interval; SUVmax,  maximum standard uptake value.
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Fig. 1　 Representative case of a 50-year-old man 
with prostate cancer (Gleason score 4+3) and PSA 
level 15.76 ng/mL.  A,  Maximum intensity projection 
(MIP) from FDG-PET showing no abnormal ﬁndings; B,  
FDG-PET/CT image showing no abnormal ﬁndings at 
the same level as panel D below; C,  MIP from 
11C-choline PET showing abnormal 11C-choline uptake 
in the right side of the prostate gland (arrow); D,  
11C-choline PET/CT image showing moderate 
11C-choline uptake (SUVmax 5.22) in the right side of 
the prostate (arrow),  reﬂecting primary prostate can-
cer.
Fig. 2　 A 66-year-old man with a PSA level of 
4.68 ng/mL who underwent radiotherapy and andro-
gen-deprivation therapy for prostate cancer (cT4N0M0,  
initial PSA 79.5 ng/mL),  in whom pelvic node and bone 
metastasis was found.  A,  MIP from FDG PET showing 
three abnormal FDG uptake spots in the pelvis; B,  
FDG-PET/CT image showing no abnormal ﬁndings at 
the same level as panel D below; C,  MIP from 
11C-choline PET showing four abnormal 11C-choline 
uptake spots in the pelvis,  including the right internal 
iliac area (arrow); D,  11C-choline PET/CT image 
showing strong 11C-choline uptake (SUVmax 6.35) in the 
right 6-mm internal iliac node (arrow),  suggesting 
lymph node metastasis; E,  11C-choline PET/CT image 
showing strong 11C-choline uptake in the right 14-mm 
external iliac (SUVmax 13.90) and left 8-mm external 
iliac (SUVmax 9.01) nodes (arrows),  reﬂecting lymph 
node metastasis; F,  11C-choline PET/CT image show-
ing strong 11C-choline uptake (SUVmax 11.77) in the 
right acetabular cartridge (arrow),  reﬂecting bone 
metastasis.
A
B D
C
A
B D
E F
C
(Table 3).  A representative case is shown in Fig. 2.
Bone metastasis. Thirteen (65%) of the 20 
patients were shown to have 153 metastatic bone lesions 
(14 cervical vertebra,  28 thoracic vertebra,  16 lumbar 
vertebra,  13 sacral vertebra,  three sternum,  2 clavicle,  
12 rib,  nine scapula,  14 iliac bone,  8 pubic,  8 ischium,  
10 acetabulum,  5 upper extremities,  8 lower extremi-
ties,  3 skull).  The patient-based and lesion-based sen-
sitivity of 11C-choline PET/CT compared to FDG-PET/
CT was 84.69% (11/13) versus 76.9% (10/13) and 94.8% 
(145/153) versus 83.0% (127/153) (p = 1.0 and 
p < 0.00001),  respectively (Tables 2 , 3).  Eight false-neg-
ative cases shown by 11C-choline PET/CT were com-
posed of 1 cervical vertebral,  1 thoracic vertebra,  1 
lumbar vertebra,  1 sacral vertebra,  2 scapula,  and 2 rib 
locations.  The SUVmax values of the 153 bone metasta-
ses shown by both 11C-choline PET/CT and FDG-PET/
CT were 5.59 ± 2.60 and 4.43 ± 2.96,  respectively 
(p< 0.0001) (Table 3).  Two representative cases are 
shown in Fig.  2 and 3.
Of the 153 metastatic bony lesions,  109 (71.2%) 
were osteoblastic,  13 (8.5%) were osteolytic,  three 
(2.0%) were mixed,  and 28 (18.3%) were invisible 
according to the CT morphological type (Table 4).  The 
visualization rate of 11C-choline compared to FDG PET/
CT was 94.5% versus 84.4% for the osteoblastic type,  
84.6% versus 45.5% for the osteolytic type,  100% ver-
sus 100% for the mixed type,  and 100% versus 96.4% 
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Fig. 3　 A 69-year-old man with a PSA level of 
4.52 ng/mL who underwent androgen-deprivation ther-
apy for prostate cancer (cT3N1M1,  initial PSA 221 ng/
mL),  in whom bone metastasis was found; A,  MIP 
from FDG PET showing no abnormal ﬁndings; B,  
FDG-PET/CT image showing no abnormal FDG uptake 
in the region of osteoblastic change in the left pubic 
area (arrow) at the same level as D below,  suggesting 
an absence of viability; C,  MIP from 11C-choline PET 
showing 2 abnormal 11C-choline uptake spots in the left 
inferior clavicular and left pubic (arrow) areas.  The 
abnormal uptake in the left inferior clavicular area was 
thought to be physiological uptake pooled in the left 
subclavian vein; D,  11C-choline PET/CT image show-
ing moderate 11C-choline uptake (SUVmax 4.45) in the 
region of osteoblastic change in the left pubic area 
(arrow),  reﬂecting active bone metastasis.
Table 4　 The visualization rates of 11C-choline PET/CT and FDG PET/CT for the diﬀerent CT types of bone metastases
CT pattern Lesion no. (%)
Sensitivity of 
11C-choline PET/CT
Sensitivity of 
FDG PET/CT p value
SUVmax on 
11C-choline PET/CT
SUVmax on 
FDG PET/CT p value
Osteoblastic 109 (71.2%) 94.5% (103/109) 84.4% (92/109) 0.0026 5.18±2.40 4.29±2.14 0.00098
Osteolytic 13 (8.5%) 84.6% (11/13) 45.5% (5/11) 0.041 4.52±2.99 1.56±2.61 0.0018
Mixed 3 (2.0%) 100% (3/3) 100% (3/3) 1.0 8.47±4.85 6.17±2.91 0.29
Invisible 28 (18.3%) 100% (28/28) 96.4% (27/28) 1.0 7.36±2.02 6.11±4.47 0.0047
Total 153 (100%) 94.8% (145/153) 83.0% (127/153) <0.0001 5.59±2.60 4.43±2.96 <0.0001
SUVmax,  maximum standardized uptake value; PET/CT,  Positron emission tomography/computed tomography.
A
B D
C
for the invisible type.  The sensitivity of 11C-choline 
PET/CT was signiﬁcantly higher than that of FDG-
PET/CT for both the osteoblastic and osteolytic types 
(p = 0.0026 and p = 0.041,  respectively).
Discussion
In the present study,  we found that compared to 
FDG-PET/CT,  11C-choline PET/CT has signiﬁcantly 
higher sensitivity for diagnosing local recurrence or 
untreated primary prostate cancer,  as well as nodal and 
bone metastasis.  This is the ﬁrst report to present a 
comparison of 11C-choline PET/CT and FDG-PET/CT 
for staging and restaging prostate cancer in Japanese 
men.  To the best of our knowledge,  4 studies have 
directly compared the diagnostic performance of cho-
line PET/CT with that of FDG-PET/CT for the detec-
tion and localization of prostate cancer in non-Japanese 
men [6-9].  The authors of 3 of those studies reported 
that 11C-choline PET/CT has significantly higher 
patient-based sensitivity for restaging prostate cancer 
compared to FDG-PET/CT [6-8],  similar to our pres-
ent results.  The patient-based sensitivity for 11C-choline 
PET/CT compared to FDG-PET/CT in those three 
reports was 47% versus 27% [6],  68% versus 34% [7],  
and 61% versus 31% [8].  Only a single study has 
reported that 18F-fluorocholine PET/CT and FDG-PET/
CT showed the same patient-based sensitivity (79%) for 
staging and restaging prostate cancer [9].
In Western countries,  11C- and 18F-choline PET/CT 
have been successfully used for the restaging of prostate 
cancer in patients with biochemical disease recurrence 
after undergoing deﬁnitive therapy,  especially when the 
PSA level is > 1.0 ng/mL [1-3 , 11].  One systematic 
review and meta-analysis of 19 selected studies with a 
total of 1,555 patients reported pooled sensitivity of 
85.6% and pooled speciﬁcity of 92.6% [12].  Picchio et 
al.  concluded that the routine use of 11C-choline PET/
CT for the restaging of prostate cancer after a radical 
prostatectomy cannot be recommended for patients 
with a PSA value < 1 ng/mL [11].  They also commented 
that in addition to the PSA value,  the PSA doubling 
time and other clinical and pathological features,  
including locally advanced tumor (pT3a-T4) or lymph 
node involvement at the initial staging should be con-
sidered when referring patients for 11C-choline PET/
CT.  
Although choline-PET/CT has limitations for 
detecting primary prostate cancer,  it may be useful in 
the minority of newly diagnosed patients with high 
clinical suspicion of distant metastatic disease (e.g.,  
serum PSA level > 20 ng/mL,  Gleason score 8-10,  
locally advanced tumor shown by palpation and/or 
MRI) [3].  In such cases,  it would be highly desirable to 
identify patients with distant disease before they are 
exposed to the morbidity of localized therapy that may 
not be beneﬁcial.  Beheshti et al. [13] evaluated 
18F-fluorocholine PET/CT for the pretreatment staging 
of prostate cancer in 130 intermediate- and high-risk 
patients,  and they demonstrated that the patient-based 
sensitivity and speciﬁcity for the detection of metastatic 
lymph nodes ≥ 5 mm in diameter were 66% and 96%,  
respectively,  with 43 instances of bone metastasis 
detected in 13 patients.  They also estimated that the 
results of a pretreatment 18F-fluorocholine PET/CT 
examination would prompt a change of therapy in 15% 
of patients overall and 20% of high-risk patients.
The potential influence of anti-androgenic treatment 
in patients who undergo an 11C-choline examination 
remains controversial.  A signiﬁcant reduction in 
11C-choline uptake following treatment with the nonste-
roidal androgenic antagonist bicalutamide was reported 
during the staging phase of prostate cancer patients 
[14].  Conversely,  in a population of 358 patients who 
had undergone a prostatectomy and showed an 
increased PSA serum level,  androgen deprivation ther-
apy was revealed as a variable that could signiﬁcantly 
predict an increased risk of positive 11C-choline PET/
CT ﬁndings only when analyzed alone and not in com-
parison with other variables,  primarily PSA-related 
values and the Gleason score [15].  One group also 
found that the accuracy of 11C-choline PET/CT for 
detecting bone metastasis did not differ signiﬁcantly 
between hormone-resistant patients and those who did 
not receive anti-androgenic treatment [16].  Based on 
these results,  a withdrawal of anti-androgenic treat-
ment cannot be recommended for the performance of 
11C-choline PET/CT examinations in hormone-resistant 
patients.
Our study has some limitations.  First,  only a small 
number of patients at a single institution were enrolled.  
A prospective,  multicenter trial with a larger cohort 
would help to clarify the exact role of 11C-choline PET/
CT in clinical decision-making and long-term outcomes 
in a clinical setting.  Second,  the enrolled population 
was heterogeneous,  as it included patients with pre-
June 2018 Choline and FDG PET in Prostate Cancer 295
treatment and post-treatment prostate cancer and treat-
ment-naive patients,  as well as those with or without 
hormonal treatment.  Such heterogeneity likely intro-
duced confounding factors into the analysis.  Third,  the 
ideal gold standard for any analysis is the histological 
conﬁrmation of obtained ﬁndings.  However,  clinical 
follow-up is known to be a valid approach for the eval-
uation of diagnostic accuracy and response to therapy,  
and it would have been unethical to investigate all PET/
CT-detected lesions with the use of an invasive proce-
dure.  Although positive ﬁndings are easy to conﬁrm,  
negative ﬁndings only indicate that it was not possible to 
acquire positive ﬁndings during follow-up,  making it 
uncertain whether the ﬁndings are truly negative.  
Fourth,  new and more sensitive PET tracers for pros-
tate cancer,  such as 18F-FACBC and 68Ga-PSMA,  were 
recently introduced for clinical use in Western countries 
[2],  but they are not yet available in Japan.
In conclusion,  11C-choline PET/CT is a convenient 
and noninvasive one-step procedure for the staging and 
restaging of prostate cancer in Japanese men.
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